Musa Tariq Sells 116 Shares of Guardant Health (NASDAQ:GH) Stock

Posted by Brian Himes on May 21st, 2026

Guardant Health, Inc. (NASDAQ:GH – Get Free Report) Director Musa Tariq sold 116 shares of the company’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $95.96, for a total value of $11,131.36. Following the completion of the transaction, the director directly owned 8,662 shares in the company, valued at $831,205.52. This trade represents a 1.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $84.83, for a total value of $9,840.28.
On Wednesday, March 18th, Musa Tariq sold 348 shares of Guardant Health stock. The shares were sold at an average price of $88.09, for a total value of $30,655.32.

Guardant Health Stock Up 17.1%

Shares of Guardant Health stock opened at $114.97 on Thursday. The stock’s fifty day moving average is $89.98 and its two-hundred day moving average is $98.62. The company has a market capitalization of $15.25 billion, a PE ratio of -33.91 and a beta of 1.48. Guardant Health, Inc. has a 52 week low of $36.36 and a 52 week high of $120.74.

Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.07). The business had revenue of $281.27 million during the quarter, compared to the consensus estimate of $269.74 million. The firm’s revenue was up 39.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.62) earnings per share. As a group, research analysts anticipate that Guardant Health, Inc. will post -2.87 earnings per share for the current year.

Hedge Funds Weigh In On Guardant Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. Emerald Advisers LLC raised its stake in Guardant Health by 24.8% in the third quarter. Emerald Advisers LLC now owns 873,203 shares of the company’s stock valued at $54,558,000 after buying an additional 173,281 shares during the last quarter. Knights of Columbus Asset Advisors LLC purchased a new stake in Guardant Health in the third quarter valued at about $1,554,000. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Guardant Health by 54.4% in the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 301,449 shares of the company’s stock valued at $18,835,000 after buying an additional 106,263 shares during the last quarter. Erste Asset Management GmbH raised its stake in Guardant Health by 10.4% in the third quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after buying an additional 66,617 shares during the last quarter. Finally, Segall Bryant & Hamill LLC raised its stake in Guardant Health by 57.8% in the third quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after buying an additional 111,822 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

GH has been the topic of several research analyst reports. Robert W. Baird initiated coverage on Guardant Health in a research report on Tuesday, February 17th. They issued an “outperform” rating and a $120.00 price objective on the stock. Piper Sandler reaffirmed an “overweight” rating and issued a $135.00 price objective on shares of Guardant Health in a research report on Tuesday, May 12th. JPMorgan Chase & Co. increased their price target on Guardant Health from $130.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Wells Fargo & Company increased their price target on Guardant Health from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, February 20th. Finally, Stifel Nicolaus increased their price target on Guardant Health from $120.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 20th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $129.42.

Check Out Our Latest Research Report on GH

About Guardant Health

(Get Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.